Pathway Genomics Announces Commitment to Free the Data Movement at NSGC Conference - Pathway Genomics
Pathway Genomics is proud to celebrate 10 successful years as a CLIA and CAP accredited clinical laboratory!

Pathway Genomics Announces Commitment to Free the Data Movement at NSGC Conference

Free the data

SAN DIEGO, CASeptember 18, 2014 – Pathway Genomics Corporation, a global clinical genetic testing company, announced today at the National Society of Genetic Counselors’ 33rd Annual Education Conference its commitment to Free the Data, a movement dedicated to open access to genetic data and collaboration through information sharing.

With variant gene submissions currently in ClinVar, the National Institutes of Health’s public archive of reports of the relationships among human variations and phenotypes, Pathway Genomics believes that genetic mutations should not be trade secrets. By broadening access and sharing genetic information, we can collectively harness the power of the genome to improve our understanding of disease and improve healthcare for everyone.

“I am proud to support Pathway Genomics’ commitment to the Free the Data movement,” said Adrian Vilalta, Pathway’s senior director of genetics. “I strongly believe that our patients deserve to have the best, most up-to-date information about the variants found in their genomes so that they can receive the most appropriate clinical care. This is only possible when the scientific community as a whole pools its resources to reach a consensus on the interpretation of genetic findings.”


Providing broad access to genetic testing will allow the medical community to collectively diagnose disease better, faster and cheaper — offering patients more effective healthcare and reducing costs to the healthcare system.

Earlier this month, Pathway Genomics launched BreastTrueTM High Risk Panel, a blood or blood next-generation sequencing test with deletion/duplication analysis to detect mutations in seven high-risk breast cancer susceptibility genes, including BRCA1, BRCA2, CDH1, PALB2, PTEN, STK11, and TP53. Additionally, the company enhanced its existing BRCATrueTM test to include single site, reflex testing, and BRCATrue Ashkenazi Jewish (3-site).